News Search Results
Aug 21, 2025, 10:01 ET Cystoscopy and Ureteroscopy Market is Growing at 6.9% CAGR to Reach US$729.30 million by 2031; Due to Increasing Prevalence of Urological Diseases | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 21, 2025, 08:30 ET AI in Molecular Biology: Revolutionizing the Future of Biotech, Upcoming Webinar Hosted by Xtalks
The featured speaker will discuss how streamlined workflows with AI-driven platforms reduce development time and simplify research processes in biotechnology and life sciences. Attendees will learn how accelerated innovation facilitates breakthroughs in synthetic biology, drug discovery, gene therapy
More news about: Xtalks
Aug 21, 2025, 08:30 ET Multidomain Biologics: Bioanalytical Strategies and Insights, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 21, 2025, 08:30 ET Dan Kagan, Scientist.com President and COO, Named Among Top 25 BioTech and Life Sciences Executives of 2025 by The Healthcare Technology Report
and operational leadership, contributions to therapeutic innovation and platform development, and their ability to advance the broader field of biotechnology and life sciences. Scientist.com congratulates Dan Kagan and the other outstanding recipients for their exceptional
More news about: Scientist.com
Aug 21, 2025, 08:30 ET ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
investment manager based in Austin, Texas, focused on public and private equity investments in the life sciences and biotechnology sectors. The firm was founded in October 2018 by Dr. Daniel Schneeberger, who brings
More news about: ADAR1 Capital Management, LLC
Aug 21, 2025, 08:00 ET Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction
advantages clients in bringing their critical therapies to market. For more information, visit andelynbio.com. About Amplo Biotechnology, Inc. Amplo Biotechnology is a late-stage preclinical company developing regenerative AAV gene therapies with an initial focus on restoring NMJ function
More news about: Andelyn Biosciences
Aug 21, 2025, 08:00 ET STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION
Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced
More news about: Stealth BioTherapeutics Inc.
Aug 21, 2025, 08:00 ET Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Aug 21, 2025, 07:23 ET Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer
clinical report prepared for regulatory purposes. About Hamlet BioPharma Hamlet BioPharma is an innovative biotechnology company that develops scientific discoveries into drugs for the treatment of cancer and infections. The goal is to address unmet medical needs in
More news about: Hamlet BioPharma AB (publ)
Aug 21, 2025, 06:02 ET Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported
More news about: Brii Biosciences Limited
Aug 21, 2025, 02:53 ET Aquaporin announces results for first half 2025
-- Aquaporin A/S (CPH: AQP) ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today announces the Company's Half-Year Interim Report for the period January 1 – June 30,
More news about: Aquaporin A/S
Aug 21, 2025, 02:49 ET Aquaporin announces results for first half 2025
AQP) ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today announces the Company's Half-Year Interim Report for the period January 1 – June 30,
More news about: Aquaporin A/S
Aug 20, 2025, 17:46 ET Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight
Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMérieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter,
More news about: DelveInsight Business Research, LLP
Aug 20, 2025, 16:05 ET Tyra Biosciences Announces Participation at Upcoming Investor Events
Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Aug 20, 2025, 10:50 ET Global Mass Spectrometry Market to Reach USD 9.62 Billion by 2030 Amid Rising Pharmaceutical R&D, Environmental Testing, and AI-Powered Advancements: MarkNtel Advisors
in remote areas. Overall, these factors create ample growth opportunities for stakeholders in the evolving landscape of analytical techniques, biotechnology innovation, and healthcare quality control.
More news about: MarkNtel Advisors
Aug 20, 2025, 10:15 ET Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR | MarketsandMarkets™
North America accounted for the largest share of the human microbiome market. This leading position is supported by a well-established biotechnology ecosystem, strong research and development infrastructure, and the presence of major market players such as Seres Therapeutics, Seed Health, and
More news about: MarketsandMarkets
Aug 20, 2025, 09:00 ET San Diego-Area Biotech Startup Achieves Major Breakthrough in the Fight Against Rare Neurodevelopmental Disorder
for their instrumental roles in making this breakthrough possible. About Grann PharmaceuticalsGrann Pharmaceuticals is a biotechnology company pioneering mRNA lipid nanoparticle–based treatments for patients with diseases caused by the absence of a critical human protein. The company's
More news about: Grann Pharmaceuticals Inc.
Aug 20, 2025, 09:00 ET Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 20, 2025, 08:49 ET Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
UniXell as a leading biotech in the field of cell therapy for psychiatric disorders," said Dr. Chen. About UniXell Biotechnology Shanghai UniXell Biotechnology Co., Ltd. was established in 2021, focusing on cell therapy drug development for neurological diseases such as Parkinson's
More news about: UniXell Biotechnology
Aug 20, 2025, 08:37 ET Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA)
More news about: Anixa Biosciences, Inc.
Aug 20, 2025, 08:00 ET Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares,
More news about: Arthrosi Therapeutics
Aug 20, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
million. The offering closed successfully in June. In June, CollPlant announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine,
More news about: CollPlant
Aug 19, 2025, 14:18 ET Kodiak Sciences to Present at American Chemical Society Fall 2025
Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present
More news about: Kodiak Sciences Inc.
Aug 19, 2025, 14:05 ET Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge
More news about: Myosin Therapeutics Inc.
Aug 19, 2025, 11:30 ET Convoke Raises $8.6M to Build the AI Operating System for Biopharma
Capital, Audacious, Lux Capital, and angels including Qasar Younis, Erik Torenberg, and other leaders in AI and biotechnology. The funding comes as biopharma companies are under pressure to reduce development cycle times and improve efficiency. New drugs spend ~45%
More news about: Convoke Holdings, Inc.